Pfizer will no longer conduct research and development into finding new drugs to treat Alzheimer's and Parkinson's diseases.
The pharmaceutical company made the announcement on Saturday, and it estimates it will cut 300 jobs from its neuroscience discovery and early development programs, Reuters reports. Pfizer, along with GlaxoSmithKline and Eli Lilly, is part of the Dementia Discovery Fund; in 2012, it saw its drug bapineuzumab, made in partnership with Johnson & Johnson for people with mild to moderate Alzheimer's, fail in the second round of clinical trials.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
'Many of us have warned for years of a rising ecofascist threat in response to climate chaos'Instant Opinion Opinion, comment and editorials of the day
-
Is this the end of cigarettes?Today's Big Question An FDA rule targets nicotine addiction
-
A beginner's guide to exploring the AmazonThe Week Recommends Trek carefully — and respectfully — in the world's largest rainforest
-
US port strike averted with tentative labor dealSpeed Read The strike could have shut down major ports from Texas to Maine
-
Biden expected to block Japanese bid for US SteelSpeed Read The president is blocking the $14 billion acquisition of U.S. Steel by Japan's Nippon Steel, citing national security concerns
-
Judges block $25B Kroger-Albertsons mergerSpeed Read The proposed merger between the supermarket giants was stalled when judges overseeing two separate cases blocked the deal
-
Rupert Murdoch loses 'Succession' court battleSpeed Read Murdoch wanted to give full control of his empire to son Lachlan, ensuring Fox News' right-wing editorial slant
-
Bitcoin surges above $100k in post-election rallySpeed Read Investors are betting that the incoming Trump administration will embrace crypto
-
Enron mystery: 'sick joke' or serious revival?Speed Read 23 years after its bankruptcy filing, the Texas energy firm has announced its resurrection
-
US charges Indian tycoon with bribery, fraudSpeed Read Indian billionaire Gautam Adani has been indicted by US prosecutors for his role in a $265 million scheme to secure solar energy deals
-
Boeing machinists approve contract, end strikeSpeed Read The company's largest union approved the new contract offer, ending a seven-week strike
